- Home
- ENGN vs PGEN Comparison
ENGN vs PGEN Comparison
Compare ENGN & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- PGEN
- Stock Information
- Founded
- ENGN 1999
- PGEN 1998
- Country
- ENGN Canada
- PGEN United States
- Employees
- ENGN 33
- PGEN N/A
- Industry
- ENGN
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- ENGN
- PGEN Health Care
- Exchange
- ENGN Nasdaq
- PGEN Nasdaq
- Market Cap
- ENGN 317.6M
- PGEN 292.6M
- IPO Year
- ENGN N/A
- PGEN N/A
- Fundamental
- Price
- ENGN $6.32
- PGEN $0.81
- Analyst Decision
- ENGN Strong Buy
- PGEN Buy
- Analyst Count
- ENGN 9
- PGEN 5
- Target Price
- ENGN $29.78
- PGEN $7.00
- AVG Volume (30 Days)
- ENGN 205.7K
- PGEN 1.1M
- Earning Date
- ENGN 12-19-2024
- PGEN 11-14-2024
- Dividend Yield
- ENGN N/A
- PGEN N/A
- EPS Growth
- ENGN N/A
- PGEN N/A
- EPS
- ENGN N/A
- PGEN N/A
- Revenue
- ENGN N/A
- PGEN $3,963,000.00
- Revenue This Year
- ENGN N/A
- PGEN N/A
- Revenue Next Year
- ENGN N/A
- PGEN $402.12
- P/E Ratio
- ENGN N/A
- PGEN N/A
- Revenue Growth
- ENGN N/A
- PGEN N/A
- 52 Week Low
- ENGN $4.42
- PGEN $0.65
- 52 Week High
- ENGN $18.40
- PGEN $1.93
- Technical
- Relative Strength Index (RSI)
- ENGN 34.04
- PGEN 46.05
- Support Level
- ENGN $5.60
- PGEN $0.71
- Resistance Level
- ENGN $6.54
- PGEN $0.79
- Average True Range (ATR)
- ENGN 0.66
- PGEN 0.05
- MACD
- ENGN -0.15
- PGEN 0.00
- Stochastic Oscillator
- ENGN 17.91
- PGEN 62.11
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.